23rd Annual
San Diego
Heart Failure Symposium
Estancia La Jolla Hotel  La Jolla, California

Advances in the
Recognition & Treatment of
Heart Failure

Friday & Saturday
June 30-July 1, 2017

Barry H. Greenberg, MD
Program Director
# The 23rd Annual San Diego Heart Failure Symposium
June 30 & July 1, 2017      Estancia La Jolla Hotel    La Jolla, California

## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgements</td>
<td>3</td>
</tr>
<tr>
<td>Course Information</td>
<td>4</td>
</tr>
<tr>
<td>Course Description, Objectives, Target Audience, Needs Assessment,</td>
<td></td>
</tr>
<tr>
<td>Accreditation Statement, HFSA Statement, Cultural and Linguistic</td>
<td></td>
</tr>
<tr>
<td>Competency Statement</td>
<td></td>
</tr>
<tr>
<td>Faculty List</td>
<td>6</td>
</tr>
<tr>
<td>Faculty Disclosures</td>
<td>7</td>
</tr>
<tr>
<td>UCSD Advanced Heart Failure Treatment Program</td>
<td>8</td>
</tr>
<tr>
<td>Goals and Activities, Statement of Purpose, Physician Directory</td>
<td></td>
</tr>
<tr>
<td>Program</td>
<td>9</td>
</tr>
<tr>
<td>Faculty Bios</td>
<td></td>
</tr>
<tr>
<td>Program Director</td>
<td>11</td>
</tr>
<tr>
<td>Barry H. Greenberg, MD, FACC</td>
<td></td>
</tr>
<tr>
<td>Guest Faculty</td>
<td></td>
</tr>
<tr>
<td>Uri Elkayam, MD, FACC</td>
<td>12</td>
</tr>
<tr>
<td>Gregg Fonarow, MD, FACC, FAHA, FHFSA</td>
<td>13</td>
</tr>
<tr>
<td>Lorraine S. Evangelista, PhD</td>
<td>14</td>
</tr>
<tr>
<td>Christopher M. O’Connor, MD</td>
<td>15</td>
</tr>
<tr>
<td>UC San Diego Participating Faculty</td>
<td></td>
</tr>
<tr>
<td>Denise D. Barnard, MD, FACC</td>
<td>16</td>
</tr>
<tr>
<td>Daniel Blanchard, MD, FACC</td>
<td>17</td>
</tr>
<tr>
<td>Lori Daniels, MD, FACC</td>
<td>18</td>
</tr>
<tr>
<td>Julie Estes, PA</td>
<td>19</td>
</tr>
<tr>
<td>Paul Hansen, PharmD, BCACP</td>
<td>20</td>
</tr>
<tr>
<td>Robert R. Henry, MD</td>
<td>21</td>
</tr>
<tr>
<td>Trina Huynh, PharmD, BCPS, FACC, FHIRS</td>
<td>22</td>
</tr>
<tr>
<td>David Krummen, MD, FACC, FHRS</td>
<td>23</td>
</tr>
<tr>
<td>Etisham Mahmud, MD, FACC, FSCAI</td>
<td>24</td>
</tr>
<tr>
<td>Christian W. Mende, MD</td>
<td>25</td>
</tr>
<tr>
<td>Anya Narezkina, MD</td>
<td>26</td>
</tr>
<tr>
<td>Robert L. Owens, MD</td>
<td>27</td>
</tr>
<tr>
<td>David Poch, MD</td>
<td>28</td>
</tr>
<tr>
<td>Gert Victor Pretorius, MBchB</td>
<td>29</td>
</tr>
<tr>
<td>Jorge Silva Enciso, MD</td>
<td>30</td>
</tr>
<tr>
<td>Pam R. Taub, MD, FACC</td>
<td>31</td>
</tr>
<tr>
<td>Howie Tran, MD, FACC</td>
<td>32</td>
</tr>
</tbody>
</table>
ACKNOWLEDGMENTS

We would like to acknowledge the following companies and organizations for their support of this symposium.

Amgen
Novartis Pharmaceuticals Corporation
Janssen Pharmaceuticals, Inc.

Advancing Knowledge in Healthcare
Otsuka America Pharmaceuticals, Inc.

Abbott
Actelion Pharmaceuticals

Boehringer Ingelheim Lilly
Boston Scientific
Regeneron - Sanofi
Relyspa
ZOLL LifeVest
Medtronic

Accent Care
Arbor Pharmaceuticals
Astellas
Boehringer Ingelheim
GE Healthcare
Gilead Sciences
Heart Failure Society of America, Inc.
Nurturing Care Senior Placement
UC San Diego Health
ABOUT THE SYMPOSIUM
Heart failure remains a major public health problem in the U.S. despite considerable advances in our understanding of its causes and the development of new approaches for treatment. To meet the substantial challenges posed by the growing heart failure population and improve outcomes in our patients, the 23rd Annual San Diego Heart Failure Symposium has been structured to highlight important emerging strategies in a series of talks and discussions aimed at helping the audience discover the best means of utilizing new approaches in managing patients. Topics that will be covered extend from preventing heart failure by managing risk factors to treating heart failure in all its stages. During the Symposium, there will be in-depth discussion of topics ranging from drugs to devices and non-pharmacologic treatments to invasive monitoring approaches.

In order to cover the wide range of exciting topics, the expanded Symposium will start Friday afternoon and extend through late Saturday afternoon. The Friday sessions will present some of the most stimulating talks of the entire meeting and will be followed by an outstanding industry sponsored reception and lecture. The 3rd Annual Stanley Lloyd M.D. lecture at this year’s meeting will be presented by Dr. Christopher O’Connor, editor in chief JACC: Heart Failure and President Elect of Heart Failure Society of America. As in the past, the Symposium offers a unique opportunity to meet and interact with both your colleagues and the renowned faculty that has been assembled from UCSD and other institutions. I hope that you will be able to join us for both the Friday afternoon and Saturday sessions of the 23rd Annual San Diego Heart Failure Symposium. I very much look forward to seeing you there.

NEEDS ASSESSMENT
Heart failure (HF) is common, affecting nearly 5 million Americans. It is also one of the few cardiovascular disorders for which prevalence figures are increasing. An estimated 670,000 new cases of heart failure are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years). Overall, heart failure is the number one cause of hospitalizations of the elderly in the U.S.

Knowledge about heart failure is accumulating so rapidly that individual clinicians may be unable to readily and adequately synthesize new information into effective strategies of care for patients with this syndrome. This year’s Symposium will provide a comprehensive overview of current evidence based therapies and treatment strategies as well as emerging approaches for treatment.

TARGET AUDIENCE
The target audience for this activity includes cardiologists, internists, primary care physicians, nurses and allied healthcare professionals.

SYMPOSIUM OBJECTIVES
At the conclusion of this program, the participant should be able to:
1. Summarize current and emerging treatments for heart failure, describe new guideline updates and provide practical information to help in the implementation of recommended therapies in individual patients.
2. Review strategies for implementing medical and device therapies that will enhance prevention and lead to improved outcomes in heart failure patients.
3. Define how specific populations including minorities, women and the elderly respond to various approaches to treating hypertension and heart failure.

ACCREDITATION
This live activity, 23rd Annual San Diego Heart Failure Symposium, with a beginning date of 06/30/2017, has been reviewed and is acceptable for up to 9.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award.

AANP: The American Academy of Nurse Practitioners accepts AAFP Prescribed credit. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

ANCC: According to the ANCC, the continuing education hours approved by the AAFP meet the ANCC-accredited CNE criteria.

AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed credit for AAPA Category 1 CME credit.

HEART FAILURE SOCIETY OF AMERICA
Officially endorsed by the Heart Failure Society of America. The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.

continued on following page
The 23rd Annual
San Diego Heart Failure Symposium
June 30 & July 1, 2017      Estancia La Jolla Hotel      La Jolla, California
The 23rd Annual
San Diego Heart Failure Symposium

**UC SAN DIEGO PROGRAM DIRECTOR**

Barry H. Greenberg, MD, FACC
Distinguished Professor of Medicine
Director, Advanced Heart Failure
Treatment Program
UCSD Medical Center
San Diego, CA

**GUEST FACULTY**

Uri Elkayam, MD, FACC
Professor of Medicine
Division of Cardiology
University of Southern California
Los Angeles, CA

Gregg Fonarow, MD, FACC, FAHA, FHFSA
Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson – UCLA Cardiomyopathy Center
Co-Chief, UCLA Division of Cardiology
Co-Director – UCLA Preventative Cardiology
University of California, Los Angeles
Los Angeles, CA

Lorraine S. Evangelista, PhD
Professor and Director of the PhD Program
Sue and Bill Gross School of Nursing
University of California, Irvine
Irvine, CA

Christopher M. O’Connor, MD
CEO and Executive Director, Inova Heart and Vascular Institute
Professor of Medicine, Duke University
Editor-in-Chief, JACC: Heart Failure
President Elect, Heart Failure Society of America
Falls Church, VA

**UC SAN DIEGO PARTICIPATING FACULTY**

Denise D. Barnard, MD, FACC
Clinical Professor of Medicine, Cardiology
Advanced Heart Failure Treatment Program
Cardiac Transplantation and LVAD Program
UCSD Health Systems

Christian W. Mende, MD
Clinical Professor of Medicine

Anya Narezkina, MD
Assistant Professor of Medicine
Division of Cardiovascular Medicine

Robert L. Owens, MD
Assistant Professor of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine

Julie Estes, PA
Heart Failure Physician Assistant

David Poch, MD
Associate Professor of Medicine
Division of Pulmonary and Critical Care

Paul Hansen, PharmD, BCACP
Clinical Pharmacist
PGY2 Residency Program Director, Transitions of Care
Assistant Clinical Professor
Shanm School of Pharmacy and Pharmaceutical Sciences at UC San Diego

Gert Victor Pretorius, MBchB
Associate Clinical Professor of Surgery
Surgical Director of Heart Transplant and Mechanical Assist Program

Jorge Silva Enciso, MD
Assistant Professor of Medicine
Heart Failure and Transplant Cardiology

Trina Huynh, PharmD, BCPP
Pharmacist, Transitions of Care Coordinator
UC San Diego Health Department of Pharmacy

Pam R. Taub, MD, FACC
Associate Professor of Medicine
Director of Hannah and Gene Step Cardiac Wellness & Rehabilitation Center
Division of Cardiovascular Medicine

David Krummen, MD, FACC, FHRS
Professor of Medicine
Director of Cardiac Electrophysiology, VA San Diego Healthcare System
Electrophysiologist, UCSD Medical Center

Howie Tran, MD, FACC
Assistant Professor of Medicine
Division of Cardiovascular Medicine
Advanced Heart Failure, Mechanical Circulatory Support and Transplant Cardiology

Etisham Mahmud, MD, FACC, FSCAI
Professor of Medicine/Cardiology
Division Chief, Cardiovascular Medicine
Director, Sulpizio Cardiovascular Center – Medicine
Director, Interventional Cardiology/CV Cath Labs
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

<table>
<thead>
<tr>
<th>Name</th>
<th>Name of Commercial Interest</th>
<th>Nature of Relevant Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uri Elkayam, MD</td>
<td>Relypsa, Novartis Pharmaceuticals</td>
<td>Speakers' Bureau/Speakers’ Bureau Consultant</td>
</tr>
<tr>
<td>Gregg Fonarow, MD</td>
<td>Medtronic, Novartis Pharmaceuticals, Janssen Pharmaceuticals, Amgen, ZS Pharma, St. Jude Medical</td>
<td>Consultant, Consultant, Consultant, Consultant, Consultant, Consultant, Consultant</td>
</tr>
<tr>
<td>Barry Greenberg, MD</td>
<td>Novartis Pharmaceuticals, Otsuka America Pharmaceuticals, Inc.</td>
<td>Consultant/Speakers’ Bureau, Speakers’ Bureau</td>
</tr>
<tr>
<td>David Krummen, MD</td>
<td>Abbott Laboratories, Vektor Medical</td>
<td>Consultant, Equity, Creator of Intellectual Property Owned by UCSD and Leased to Vektor Medical</td>
</tr>
<tr>
<td>Lori Daniels, MD</td>
<td>Roche, Critical Diagnostics, Siemens</td>
<td>Speakers’ Bureau/Advisory Board, Speaker’s Fees, Independent Contractor</td>
</tr>
<tr>
<td>Christopher O’Connor, MD</td>
<td>ResMed, LLC, BMS, Merek</td>
<td>Consultant, Consultant, Consultant</td>
</tr>
<tr>
<td>Robert Owens, MD</td>
<td>ResMed, LLC</td>
<td>Honorarium and Travel Fees</td>
</tr>
<tr>
<td>David Poch, MD</td>
<td>Bayer</td>
<td>Consultant/Speakers’ Bureau</td>
</tr>
<tr>
<td>Pam Taub, MD</td>
<td>Amgen, Sanofi Regeneron</td>
<td>Speakers’ Bureau/Speakers’ Bureau</td>
</tr>
</tbody>
</table>

The following have no relevant financial relationships to disclose: Denise Barnard, MD, Daniel Blanchard, MD, Jorge Silva Enciso, MD, Julia Estes, PA, Lorraine Evangelista, PhD, Paul Hansen, PharmD, Robert Henry, MD, Trina Huynh, PharmD, Ehtisham Mahmud, MD Christian Mende, MD, Anna Narezkina, MD, Gert Victor Pretorius, MBchB, Hao Tran, MD

The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose.

This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product.
The UCSD Advanced Heart Failure Treatment Program (AHFTP) is dedicated to working with community and university based physicians to provide the most beneficial and cost effective medical care for patients with advanced heart failure.

The AHFTP combines the skills of a dedicated and highly experienced health care team with the extensive resources of the UC San Diego Sulpizio Cardiovascular Center in order to optimally manage heart failure patients.

The development of new approaches to the treatment of heart failure is a fundamental goal of the program. In order to accomplish this we combine the diverse talents of the AHFTP team with those of other researchers throughout the UC San Diego campus.

The program provides the following services:

1. Risk stratification, identification of potentially reversible causes and treatment of refractory patients. The aggressive use of conventional therapies has resulted in clinical improvement, as well as substantial reduction in hospitalization and ER visits in our patients.

2. Special programs involving the use of investigational agents in patients who remain refractory and limited by symptoms of heart failure. Novel approaches that are being evaluated for the treatment of heart failure include cell transplantation therapy (stem cell therapy), gene transfer therapy and a variety of novel drug therapies.

3. Cardiac and multi-organ transplantation.

4. Mechanical circulatory support (MCS) using a variety of short-term devices including IMPELLA and Tandem Heart and long-term devices including the Heart Mate II (HMII), HeartWare Ventricular Assist Device (HVAD) and the Total Artificial Heart (TAH).

**OUR PHYSICIANS**

<table>
<thead>
<tr>
<th>Barry H. Greenberg, MD, FACC</th>
<th>Denise D. Barnard, MD, FACC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distinguished Professor of Medicine</td>
<td>Clinical Professor of Medicine</td>
</tr>
<tr>
<td>Director, Advanced Heart Failure Treatment Program</td>
<td>Director, Women’s Cardiovascular Health Program</td>
</tr>
<tr>
<td>Division of Cardiology</td>
<td>Assistant Director, Advanced Heart Failure Treatment Program</td>
</tr>
<tr>
<td>Division of Cardiology</td>
<td>Division of Cardiology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eric Adler, MD</th>
<th>Jorge Silva Enciso, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Associate Clinical Professor</td>
<td>Assistant Clinical Professor of Medicine</td>
</tr>
<tr>
<td>Medical Director, Cardiac Transplant</td>
<td>Division of Cardiology</td>
</tr>
<tr>
<td>Division of Cardiology</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Howie Tran, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assistant Clinical Professor of Medicine</td>
</tr>
<tr>
<td>Division of Cardiology</td>
</tr>
</tbody>
</table>

**REFERRALS & INQUIRIES**

<table>
<thead>
<tr>
<th>OFFICE ADMINISTRATION</th>
<th>CLINICAL RESEARCH COORDINATORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Covarrubias</td>
<td>Melanee Schimmel, BSN, RN</td>
</tr>
<tr>
<td>Administrative Assistant</td>
<td>Telephone: 858-657-5374</td>
</tr>
<tr>
<td>Telephone: 858-657-7150</td>
<td>Fax: 858-657-5028</td>
</tr>
<tr>
<td>Fax: 858-657-5028</td>
<td>Email: <a href="mailto:mschimmel@ucsd.edu">mschimmel@ucsd.edu</a></td>
</tr>
<tr>
<td>Email: <a href="mailto:ecovarrubias@ucsd.edu">ecovarrubias@ucsd.edu</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HEART FAILURE CLINICAL REFERRALS</th>
<th>TRANSPLANT OR LVAD REFERRALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michelle Ogata Rubin</td>
<td>Sara Mundo</td>
</tr>
<tr>
<td>Clinic Assistant</td>
<td>Heart Transplant Assistant</td>
</tr>
<tr>
<td>Telephone: 858-657-8817</td>
<td>Telephone: 858-657-5050</td>
</tr>
<tr>
<td>Fax: 858-657-1252</td>
<td>Fax: 858-657-5044</td>
</tr>
<tr>
<td>Email: <a href="mailto:mogata@ucsd.edu">mogata@ucsd.edu</a></td>
<td>Email: <a href="mailto:smundovalle@ucsd.edu">smundovalle@ucsd.edu</a></td>
</tr>
</tbody>
</table>
The 23rd Annual
San Diego Heart Failure Symposium
Advances in the Recognition & Treatment of Heart Failure
June 30 & July 1, 2017      Estancia La Jolla Hotel      La Jolla, California

FRIDAY, JUNE 30, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-1:00pm</td>
<td>Registration - Pacifica Ballroom Foyer</td>
</tr>
</tbody>
</table>
| 1:00-1:25pm | **FRIDAY SESSION I**  
Barry Greenberg, MD - Moderator  
**Effects of Transitional Care Models on Patients with End-Stage Heart Failure: What Does the Evidence Show?**  
Lorraine Evangelista, PhD |
| 1:25-1:50pm | **Use of SGLT2 Inhibitors to Prevent Cardiovascular Disease in Diabetics**  
Robert Henry, MD |
| 1:50-2:15pm | **Treating Hypertension to Prevent Heart Failure: What Are the Best Approaches?**  
Christian Mende, MD |
| 2:15-2:40pm | **Pulmonary Hypertension: Classification and Treatment Options**  
David Poch, MD |
| 2:40-3:05pm | **Question/Answer Panel - Dr. Greenberg (Moderator)**  
Drs. Taub, Henry, Mende and Paul Hansen, PharmD (Panelists) |
| 3:05-3:30pm | Break                                                                     |
| 3:30-3:55pm | **FRIDAY SESSION II**  
Barry Greenberg, MD - Moderator  
**How to Recognize and Treat Depression and Mood Disorders in Heart Failure Patients**  
Christopher O’Connor, MD |
| 3:55-4:20pm | **Chemotherapy Induced Cardiomyopathy**  
Anya Narezkina, MD |
| 4:20-4:45pm | **Management of Patients with Recovered EF**  
Barry Greenberg, MD |
| 4:45-5:10pm | **Management of Hyperlipidemia in 2017 - New Targets and New Agents**  
Gregg Fonarow, MD |

ADDITIONAL FRIDAY SESSION (CME AVAILABLE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 5:10-6:25pm | **Mini Satellite Symposium (CME Credit by AKH)**  
The New Age of Heart Failure: Innovative Diagnostic and Treatment Strategies  
Barry Greenberg, MD  

ADDITIONAL FRIDAY SESSION (NON-CME)

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 6:30-8:00pm | **Reception with Hors d’oeuvres/Presentation - Pacifica Ballroom**  
(Non-CME)  
**Therapies in Cardiovascular Disease: Corlanor® (ivabradine)**  
Product Overview & Repatha® (evolocumab) Product Overview  
Pam Taub, MD |

Please note, this session is not part of the accredited educational activity (credit is not offered for attending). Optional to attend.
### SATURDAY, JULY 1, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45-7:10am</td>
<td>Registration/Visit Exhibits - La Jolla Ballroom</td>
</tr>
<tr>
<td>7:10-8:10am</td>
<td>Breakfast - Pacifica Ballroom</td>
</tr>
<tr>
<td>7:10-8:10am</td>
<td>Additional Session* - Pacifica Ballroom</td>
</tr>
<tr>
<td>8:10-8:20am</td>
<td>Welcome and Introductions - La Jolla Ballroom</td>
</tr>
<tr>
<td></td>
<td>Barry Greenberg, MD - Program Director</td>
</tr>
</tbody>
</table>

**SATURDAY SESSION I**  
Barry Greenberg, MD - Moderator

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:20-8:40am</td>
<td>State of the Art I: Preventing Sudden Cardiac Death in Heart Failure and Post-MI Patients</td>
</tr>
<tr>
<td></td>
<td>David Krummen, MD</td>
</tr>
<tr>
<td>8:40-9:10am</td>
<td>Third Annual Stanley Lloyd, MD Lecture</td>
</tr>
<tr>
<td></td>
<td>New Strategies in the Management of Heart Failure</td>
</tr>
<tr>
<td></td>
<td>Christopher O’Connor, MD</td>
</tr>
<tr>
<td>9:10-9:30am</td>
<td>Vasodilator Therapy of Chronic Heart Failure</td>
</tr>
<tr>
<td></td>
<td>Uri Elkayam, MD</td>
</tr>
<tr>
<td>9:30-9:50am</td>
<td>Cardiac Rehabilitation: Current and Future Directions</td>
</tr>
<tr>
<td></td>
<td>Pam Taub, MD</td>
</tr>
<tr>
<td>9:50-10:10am</td>
<td>Question/Answer Panel - Dr. Greenberg (Moderator)</td>
</tr>
<tr>
<td></td>
<td>Drs. Taub, Krummen, O’Connor, Maisel and Julia Estes, PA (Panelists)</td>
</tr>
<tr>
<td>10:10-10:30am</td>
<td>Coffee Break/Visit Exhibits</td>
</tr>
</tbody>
</table>

**SATURDAY SESSION II**  
Denise Barnard, MD - Moderator

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:50am</td>
<td>The 2016 Heart Failure Guideline Updates - Will Use of Sacubitril/Valsartan and Ivabradine Improve Patient Outcomes?</td>
</tr>
<tr>
<td></td>
<td>Gregg Fonarow, MD</td>
</tr>
<tr>
<td>10:50-11:10am</td>
<td>Drugs and Devices to Prevent Stroke in Atrial Fibrillation</td>
</tr>
<tr>
<td></td>
<td>Daniel Blanchard, MD</td>
</tr>
<tr>
<td>11:10-11:30am</td>
<td>Sleep Disordered Breathing in Heart Failure: Diagnosis and Treatment</td>
</tr>
<tr>
<td></td>
<td>Robert L. Owens, MD</td>
</tr>
<tr>
<td>11:30-11:50am</td>
<td>Role of Biomarkers in the Management of Heart Failure Patients</td>
</tr>
<tr>
<td></td>
<td>Lori Daniels, MD</td>
</tr>
<tr>
<td>11:50-12:10pm</td>
<td>Case Presentation - Dr. Barnard (Presenter)</td>
</tr>
<tr>
<td></td>
<td>Drs. Fonarow, Owens, Elkayam and Trina Huynh, Pharm D (Panelists)</td>
</tr>
<tr>
<td>12:20-1:40pm</td>
<td>Lunch - Pacifica Ballroom</td>
</tr>
<tr>
<td>12:20-1:40pm</td>
<td>Additional Session** - Pacifica Ballroom</td>
</tr>
</tbody>
</table>

**SATURDAY SESSION III**  
Howie Tran, MD - Moderator

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:40-2:05pm</td>
<td>State of the Art II: Valvular Disease and Heart Failure: Role of Catheter Based Interventions</td>
</tr>
<tr>
<td></td>
<td>Etisham Mahmud, MD</td>
</tr>
<tr>
<td>2:05-2:25pm</td>
<td>Monitoring Devices to Detect Worsening HF and Prevent Hospitalizations</td>
</tr>
<tr>
<td></td>
<td>Gregg Fonarow, MD</td>
</tr>
<tr>
<td>2:25-2:45pm</td>
<td>Management of Acute Heart Failure - Barry Greenberg, MD</td>
</tr>
<tr>
<td>2:45-3:05pm</td>
<td>Coffee Break/Visit Exhibits</td>
</tr>
<tr>
<td>3:05-3:25pm</td>
<td>Using Vaptans to Treat Heart Failure Patients</td>
</tr>
<tr>
<td></td>
<td>Jorge Silva Enciso, MD</td>
</tr>
<tr>
<td>3:25-3:45pm</td>
<td>State of the Art III: The Surgical Management of Acute Heart Failure</td>
</tr>
<tr>
<td></td>
<td>Gert Victor Pretorius, MBchB</td>
</tr>
<tr>
<td>3:45-4:05pm</td>
<td>Rationale for New Approaches for Treating Hyperkalemia in HF</td>
</tr>
<tr>
<td></td>
<td>Uri Elkayam, MD</td>
</tr>
<tr>
<td>4:05-4:30pm</td>
<td>Q/A Session - Dr. Tran (Moderator), Drs. Mahmud, Fonarow, Greenberg, Enciso Silva and Pretorius (Discussants)</td>
</tr>
<tr>
<td>4:30pm</td>
<td>Adjourn Session</td>
</tr>
</tbody>
</table>

**ADDITIONAL SATURDAY SESSIONS - (NON-CME)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:10-8:10am</td>
<td>* Breakfast Lecture - Pacifica Ballroom - (Non-CME)</td>
</tr>
<tr>
<td></td>
<td>THROMBOSIS: Atrial fibrillation - An Exploration in Risk Reduction - Uri Elkayam, MD</td>
</tr>
<tr>
<td>12:20-1:40pm</td>
<td>** Luncheon Lecture - Pacifica Ballroom - (Non-CME)</td>
</tr>
<tr>
<td></td>
<td>Putting Guidelines into Practice: New Recommendations for Optimal Treatment of HFrEF</td>
</tr>
<tr>
<td></td>
<td>Barry Greenberg, MD</td>
</tr>
</tbody>
</table>

Please note, these sessions are not part of the accredited educational activity (credit is not offered for attending). Optional to attend.
Barry H. Greenberg, MD, FACC
Distinguished Professor of Medicine
Director, Advanced Heart Failure Treatment Program
UCSD Medical Center

Barry H. Greenberg, MD, is Distinguished Professor of Medicine and Director of the Advanced Heart Failure Treatment Program at the University of California, San Diego School of Medicine (UCSD). He earned a medical degree from the State University of New York Upstate Medical University College of Medicine in Syracuse. He completed his internship at George Washington University Hospital in Washington, DC and residency in internal medicine at Yale-New Haven Hospital in New Haven, Connecticut. Following further research training at the Lipid Metabolism Branch of the National Heart, Lung, and Blood Institute in Bethesda, Maryland and the Cardiovascular Research Institute of the University of California, San Francisco School of Medicine (UCSF), he completed a fellowship in cardiology at UCSF. He then joined the faculty of Oregon Health Sciences University School of Medicine in Portland. Prior to arriving at his present position at UCSD, he was a visiting professor in residence at both the Royal Postgraduate Medical School in London, England and the Laboratoire de Médicine Expérimentale of the Collège de France in Paris.

Dr. Greenberg serves on the executive steering and data safety monitoring committees of numerous national and international clinical trials in heart failure. He is a founding member and a past President of the Heart Failure Society of America (HFSA).

Dr. Greenberg has longstanding interests in the basic cellular mechanisms of heart failure and the development of new forms of therapy. He has published extensively in these areas. He is co-editor of Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management, the first comprehensive text in this field, now in its 3rd edition and editor of Myocardial Remodeling: Mechanisms and Treatment, published in 2006 and Management of Heart Failure published in 2010. He is co-author of Contemporary Diagnosis and Management of Congestive Heart Failure. He is an associate editor of the Journal of the American College of Cardiology, and he sits on the editorial boards of several other cardiology specialty and subspecialty journals. Dr. Greenberg has been recognized by his peers numerous times over the years as one of the “Best Doctors in America” and “Best Doctors in San Diego.”
Uri Elkayam, MD, FACC
Professor of Medicine
Division of Cardiology
University of Southern California
Los Angeles, CA

Uri Elkayam, MD received his medical degree from the Tel-Aviv University, Israel, in 1973 and is presently Professor of Medicine (Cardiology) at the University of Southern California in Los Angeles. He is a past member of the executive council and chairman of the corporate affairs committee of the American Society of Cardiac Failure. Doctor Elkayam is a member of the editorial boards of the American Journal of Cardiology, JACC heart failure, Cardiology, Journal of cardiovascular pharmacology and Therapeutics and Cardiology in Review and a past member of the editorial boards of JACC and the Journal of Cardiac Failure. He is a fellow of the American College of Cardiology, American Heart Association and American College of chest physicians.

Doctor Elkayam’s research and clinical interests are in the areas of congestive heart failure, heart disease and pregnancy, valvular heart disease, cardiomyopathies and cardiovascular pharmacology. He has been involved in more than 100 self initiated; NIH and industry funded research projects and served in a leading position in numerous national and international multi-center studies. He is the author or co-author on over 180 publications and over 80 book chapters and has the distinction of being listed in Best Doctors in America and America's Top Doctors from 2001 to 2013 and as one of the top 100 most influential Israelis in the U.S. in 2011.
Gregg C. Fonarow, MD, FACC, FAHA, FHFSAA
Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson – UCLA Cardiomyopathy Center
Co-Chief, UCLA Division of Cardiology
Co-Director – UCLA Preventative Cardiology
University of California, Los Angeles
Los Angeles, CA

Gregg C. Fonarow, MD, FACC, FAHA is the Eliot Corday Professor of Cardiovascular Medicine and Science at the University of California, Los Angeles. He serves as Director of the Ahmanson-UCLA Cardiomyopathy Center, Co-Director of UCLA’s Preventative Cardiology Program, and Clinical Co-Chief of Cardiology, UCLA Division of Cardiology. He attained the rank of Professor of Medicine, Geffen School of Medicine at UCLA in 2003. His research interests center on acute and chronic heart failure, preventative cardiology, quality of care, outcomes, and implementing systems of care to improve clinical outcomes. Dr. Fonarow has published over 800 research studies and clinical trials in heart failure, disease management, preventative cardiology, and quality of care/outcomes research. New therapies and management strategies for advanced heart failure and research into the pathophysiology of this disease are conducted at UCLA under his direction. He has also developed and successfully implemented a comprehensive atherosclerosis treatment program at the UCLA Medical Center (Cardiovascular Hospitalization Atherosclerosis Management Program: CHAMP), which served as the model for the American Heart Association’s Get With The Guidelines Program. Dr. Fonarow serves on the steering committee for the AHA’s Get With The Guidelines Program and was national principle investigator of ADHERE and OPTIMIZE-HF. He served as co-chair of IMPROVE-HF. He is on the steering committee and serves as an investigator for a number of randomized clinical trials in heart failure. He serves as a reviewer and serves on the editorial boards for a number of leading cardiovascular journals. Dr. Fonarow received the outstanding UCLA Cardiology Faculty Teaching Award in 1997 and was honored by the American College of Cardiology with the W. Proctor Harvey Young Teacher Award in 1998. He was awarded the Eliot Corday Chair in Cardiovascular Medicine and Science in 2003. He received an AHA Award of Meritorious Achievement in 2004. In 2009, he received the Raymond D. Bahr Award of Excellence and the Turning Guidelines into Lifelines Award from the AHA. In 2015, he received the Clinical Research Forum’s Distinguished Clinical Research Achievement Award.
Lorraine S. Evangelista, PhD
Professor and Director of the
PhD Program
Sue and Bill Gross
School of Nursing
University of California, Irvine
Irvine, CA

Lorraine S. Evangelista is a Professor and Director of the PhD Program at the UC Irvine Sue and Bill Gross School of Nursing. She completed her baccalaureate training at the University of the Philippines College of Nursing (cum laude) in 1985. She received her master’s and doctoral degree from the UCLA School of Nursing in 1993 and 2000, respectively. Dr. Evangelista is a skilled clinician, researcher and educator. She has worked in the critical care setting in several nursing roles for over 15 years. As a researcher, she is recognized nationally and internationally for her investigation into the care of patients with heart disease and the effects of this disease on the patients and family members. She has over 100 publications in medical and nursing journals on adherence, self-care, psychological distress, quality of life, and health literacy. She received a 2.5 million dollar grant from the National Institute of Health in the State to examine the effects of macronutrients on delaying the progression of heart failure (2010-2016) and was part a UC system-wide consortium that was awarded 9.9 million to examine the impact of wireless technology on reducing variations in care of patients hospitalized with heart failure (2012-2015). She just completed a U.S. Fulbright scholarship to study the lifestyle behaviors and risk factors of Filipinos in underserved communities.
Christopher M. O’Connor, MD
CEO and Executive Director, Inova Heart and Vascular Institute
Professor of Medicine, Duke University
Editor-in-Chief, JACC: Heart Failure
President Elect, Heart Failure Society of America
Falls Church, VA

Christopher M. O’Connor, MD, FACC, FESC, FHFA is the Executive Director and CEO of the Inova Fairfax Heart and Vascular Institute, a 5-hospital center in the Northern Virginia / Washington, DC area. He is a Professor of Medicine in Cardiology at Duke University, and was previously the chief of the Division of Cardiology and director of the Duke Heart Center. Under his leadership, Duke Heart Center was ranked the #4 Heart Center in the country by U.S. News and World Report. Dr. O’Connor, who first joined the Duke faculty in 1989, is an internationally recognized cardiologist and authority on heart failure. His clinical investigations have dramatically expanded the understanding of numerous aspects of cardiac function and dysfunction, including the influence of depression and stress on heart failure patients. His research has led to profound insights into both pharmacologic and non-pharmacologic therapies to treat heart failure and has had a direct impact on the lives of thousands of patients. Dr. O’Connor was one of the first investigators to lead initiatives to study therapies in acute decompensated heart failure, which has led to a number of novel therapeutic interventions. He was the Principal Investigator of the landmark HF-ACTION clinical trial, which studied exercise training in more than 2,000 heart failure patients, and eventually led to a change in the international guidelines, change in the national reimbursement of cardiac rehabilitation for heart failure patients by CMS, and validation of two novel biomarkers that were later approved by the FDA. Dr. O’Connor was an editor of the textbook, Managing Acute Decompensated Heart Failure, the first one published on the topic. He is currently the editor-in-chief of the Journal of the American College of Cardiology: Heart Failure, and serves on the editorial boards for several journals, including the New England Journal of Medicine, Journal of the American Medical Association, and Journal of the American College of Cardiology. Dr. O’Connor is a Fellow of the American College of Cardiology (ACC), the European Society of Cardiology (ESC), and the Heart Failure Society of America (HFSA). He has served on over 90 CEC and DSMC committees in 25 years and served as Chair or Co-Chair on more than 15 of these committees. He has an extensive record of successful mentorship of trainees and has published over 500 manuscripts. He has served as Principal Investigator (PI) or Co-PI for over 20 national and international clinical trials with an extensive record of NIH/NHLBI and industry grants. He serves in national leadership roles in the HFSA and ACC, and is currently President-Elect of the HFSA. His commitment to mentoring students, residents, and fellows at Duke has been recognized with the Joseph C. Greenfield Research Mentoring Award in 2006 and the 2013 Research Mentoring Award for clinical science research by the Schools of Medicine and Nursing. Dr. O’Connor earned an undergraduate degree from the University of Maryland, College Park, and a medical degree from the University of Maryland, Baltimore. He went on to Duke to complete an internship, residency, chief residency, and cardiology fellowship.
Denise D. Barnard, MD, FACC
Clinical Professor of Medicine, Cardiology
Advanced Heart Failure Treatment Program
Cardiac Transplantation and LVAD Program
UC San Diego Health Systems
San Diego, California

Denise Barnard is a 1987 graduate of the University of California at San Diego School of Medicine. She subsequently completed her residency in Internal Medicine at UCSD and was selected as Chief Medical Resident. Following a fellowship in Cardiovascular Medicine at the University of California, San Diego and a post-doctoral fellowship in Transplantation Cardiology at Stanford University, she joined the faculty at the University of California, San Diego. She currently is a Professor of Medicine in the Division of Cardiology, Department of Internal Medicine.

Dr. Barnard works with Drs. Barry Greenberg, Eric Adler and Jorge Silva Enciso in both the Advanced Heart Failure Treatment Program and Cardiac Transplantation and Mechanical Circulatory Assist Device Program at UCSD Medical Centers. She is Board Certified in Advanced Heart Failure and Transplantation. She also is the co-founder of the Women’s Cardiovascular Health Program in La Jolla. Further, she serves as a part-time Attending Physician at the San Diego VA Medical Center, with weekly clinics for pre- and post-cardiac transplant patients and cardiomyopathy patients.

Dr. Barnard is actively involved in clinical research trials of heart failure both at UCSD and the VA. Dr. Barnard is presently an Editorial Board Member for the Journal of Heart and Lung Transplantation. She also serves on the Editorial Board for several other cardiology journals. Dr. Barnard has won the respect of her peers and has been consistently selected as one of the "Best Doctors in America" since 1999. Dr. Barnard is a longstanding member of the Heart Failure Society of America (HFSA) and co-authored the first two HFSA Clinical Treatment Guidelines.

Dr. Barnard has a strong interest in working with her patients toward positive health goals and believes that good communication is an essential tool in her treatment of patients. She contends patients should receive information about their condition and be able to understand what it means in terms of outcome and prognosis. She says her strengths are in active listening and her ability to translate "doctor-speak" into English. Her outside interests include gardening, cooking, golf, fishing and camping. She is an avid fan of several professional sports and appreciates a wide variety of music, but mostly country and classic rock.
Dr. Blanchard is a professor of medicine in the Division of Cardiovascular Medicine at UCSD. He is currently Director of the Cardiology Fellowship Program at UCSD. His clinical interests include general cardiology, echocardiography, and advanced cardiac imaging techniques. His research interests have focused on cardiac imaging in pulmonary hypertension and right ventricular overload.
Dr. Lori Daniels is a cardiologist at the University of California, San Diego and Director of the Coronary Care Unit. She is a graduate of Harvard College in Cambridge, Massachusetts and Harvard Medical School in Boston, Massachusetts. She completed her internship and residency at the University of California, San Diego Medical Center and subsequently served as Chief Resident in Internal Medicine there. She also completed her Fellowship in Cardiology at UCSD Medical Center, serving as Chief Fellow during her final year. She received a Masters of Advanced Studies in Clinical Research, and is a Fellow of the American College of Cardiology.

Dr. Daniels is the recipient of an American Heart Association Postdoctoral Research Grant, an American College of Cardiology/Guidant Foundation Research Grant in Women’s Cardiovascular Health, and an American Heart Association Scientist Development Grant. Her research interests focus on using biomarkers to assess cardiovascular risk in a variety of populations; she also studies cardiovascular outcomes in young adults with a childhood history of Kawasaki Disease, and coronary/pulmonary angiographic findings in patients with chronic thromboembolic pulmonary hypertension.
Julia Estes is a Physician Assistant who works in Heart Failure at University of California San Diego. She earned her undergraduate degree in Biochemistry from Allegheny College in Meadville, Pennsylvania, and her Master’s degree in Physician Assistant Studies from Chatham University in Pittsburgh, Pennsylvania. She holds a national board certification with the National Commission on Certification of Physician Assistants.
Dr. Paul Hansen received his PharmD degree in 2009 from the Medical College of Virginia at Virginia Commonwealth University. He then completed post-graduate residency training with a focus in ambulatory care at UC San Diego Health in 2010. Following completion of residency, Dr. Hansen went on to take a faculty position with Touro University – California School of Pharmacy where he partnered with Sharp Rees-Stealy Medical Group in San Diego to develop ambulatory pharmacy clinical services including partnership with a nurse-driven anticoagulation clinic as well as creation of pharmacist-run services such as lipid and refill management clinics, respectively. Dr. Hansen returned to UC San Diego Health in 2014 to assist in further developing the transitions of care programs and was named the PGY2 Transitions of Care Residency Program Director in 2016. Dr. Hansen is a board-certified ambulatory care pharmacy specialist as of 2011.
Robert R. Henry, MD  
Professor of Medicine  
Department of Medicine  
VA San Diego Healthcare System  
San Diego, CA

Robert R. Henry, MD, is Professor of Medicine in the Division of Endocrinology & Metabolism at the University of California, San Diego. He is also Chief of both the Section of Endocrinology, Metabolism & Diabetes and the Center for Metabolic Research at the VA Medical Center in San Diego.

Dr Henry received his medical degree from the University of Manitoba Medical School, Manitoba, Canada, where he also completed his residency in internal medicine and fellowship in endocrinology.

He is Past President of the American Diabetes Association Medicine and Science (2011) and is a member of the American Association of Clinical Endocrinology, the European Association for the Study of Diabetes, the Obesity Society, the Endocrine Society, Western Society for Clinical Investigation, Western Association of Physicians, the American Federation for Clinical Research and the Royal College of Physicians Edinburgh. His research is funded by the National Institutes of Health-NIDDK, the American Diabetes Association, the Department of Veterans Affairs and numerous pharmaceutical grants. Recent awards include the Distinguished Clinical Scientist Award from the American Diabetes Association, the Mary Jane Kugal Award of the Juvenile Diabetes Research Foundation International, the Robert H. Williams-Rachmiel Levine Award from the Western Metabolism Club, Frontiers in Science Award from American Association of Clinical Endocrinology and the Banting Medal for Public Service from the American Diabetes Association.

Dr Henry has published more than 400 journal articles and chapters. His current clinical research interests involve the study of new therapies for type 1 and type 2 diabetes and obesity. Basic science interests include study of the metabolic and cardiovascular effects of human skeletal muscle and adipose tissue secretory products including adiponectin, signal interactions between skeletal muscle and adipose tissue and defects of insulin signal transduction in these tissues of obese and type 2 diabetic patients.
Trina Huynh, PharmD, BCPS
Pharmacist, Transitions of Care Coordinator
UC San Diego Health
Department of Pharmacy
UC San Diego Health Systems
San Diego, CA

Trina Huynh graduated with a Doctorate of Pharmacy from University of California, San Diego Skaggs School of Pharmacy in 2013. She completed her general Acute Care Pharmacy residency at UC San Diego Health in 2014 and continued on to specialize in Transitions of Care in 2015. She remained on as staff after her residency training. In 2016, she became the Pharmacy Department’s Transitions of Care Coordinator. Her clinical area of focus remains within The Advanced Heart Failure Transitions of Care program, where she works with the multidisciplinary team to facilitate safe discharges.
David Krummen, MD, FACC, FHRS
Professor of Medicine
Director of Cardiac Electrophysiology,
VA San Diego Healthcare System
Electrophysiologist, UCSD Medical Center
UC San Diego Health Systems
San Diego, CA

Dr. David Krummen is the Director of Electrophysiology at VA San Diego and an Associate Professor of Medicine at the University of California San Diego (UCSD). His clinical and research interests include mechanisms of atrial fibrillation (AF) and ventricular fibrillation (VF). He and his team developed and reported the FIRM (Focal Impulse and Rotor Modulation) mapping technique to identify and ablate AF-sustaining sites. He discovered reported the mechanistic significant of electrical rotors to the maintenance of VF. He is also a co-investigator on a project using computational modeling to study cardiac resynchronization therapy (CRT) in heart failure patients. He attends as the Coronary Care Unit Attending at both the VA San Diego and UCSD Medical Centers, and performs ablation and device implantation procedures at both institutions.
Ehtisham Mahmud, MD, FACC, FS C AI
Professor of Medicine/Cardiology
Division Chief, Cardiovascular Medicine
Director, Sulpizio Cardiovascular Center – Medicine
Director, Interventional Cardiology/CV Cath Labs
UC San Diego Health Systems
San Diego, CA

Dr. Mahmud is professor and division chief of Cardiovascular Medicine, director of the Sulpizio Cardiovascular Center, and director of Interventional Cardiology at the University of California, San Diego. He is board-certified in cardiovascular medicine and interventional cardiology, and is a Fellow of the Society for Cardiovascular Angiography and Interventions, American College of Cardiology, and the Royal College of Physicians and Surgeons of Canada. He serves on a number of editorial boards, national committees, and is vice-president of the Society for Cardiovascular Angiography and Interventions.

Dr. Mahmud directs the interventional cardiology clinical trials center at UC San Diego. His research interests include robotics, devices used in cardiovascular interventions, and interventional approaches for the treatment of thromboembolic pulmonary hypertension. His clinical focus is on complex coronary and structural heart interventions.

Dr. Mahmud completed fellowships in coronary and peripheral vascular interventions at Emory University in Atlanta and cardiovascular medicine at UC San Diego. He completed his internal medicine residency at UC San Diego and earned his medical degree at the University of Alberta in Edmonton, Canada. He has been voted one of the top physicians in San Diego by the San Diego county medical society and among the top interventional cardiologists in the nation by U.S. News & World Report.
The 23rd Annual
San Diego Heart Failure Symposium
June 30 - July 1, 2017      Estancia La Jolla Hotel      La Jolla, California

Christian W. Mende, MD, FACP, FACN, FASN
Clinical Professor of Medicine
UC San Diego Health Systems
San Diego, CA

Dr. Mende is clinical Professor of Medicine at the University of California, San Diego. He attended the University of Heidelberg, Germany and completed an internal medicine residency in Tucson, Arizona. Dr. Mende received post-graduate training as a NIH fellow in Nephrology, at Peter Bent Brigham Hospital and Harvard Medical School and is board certified in Nephrology, Internal Medicine, and Clinical Hypertension. He is a Fellow of the American College of Physicians, Nutrition, and Nephrology.
Dr. Narezkina is an expert in cardio-oncology, she collaborates with UC San Diego Health oncologists to address the cardiac needs of patients undergoing chemotherapy or radiation therapy. This includes assessing and planning for any cardiovascular risks before cancer treatment begins, monitoring for cardiovascular complications during treatment, and providing long-term follow-up for cancer survivors to minimize or prevent later complications. Her research focuses on the prevention or early detection of heart disease, especially in cancer patients. She is studying advanced cardiac imaging for early detection of chemotherapy complications.

Dr. Narezkina completed a fellowship in cardiology and a residency in internal medicine and at UC San Diego School of Medicine. She earned her medical degree from the Smolensk State Medical Academy in Russia. She is board-certified in internal medicine, cardiovascular disease and echocardiography.
Robert L. Owens, MD
Assistant Professor of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
UC San Diego Health Systems
San Diego, CA

Dr. Robert Owens received his medical degree from the College of Physicians and Surgeons at Columbia University. He completed residency at Massachusetts General Hospital and Pulmonary and Critical Care Fellowship at Harvard. He is board certified in Internal Medicine, Pulmonary, Critical Care and Sleep Medicine. He is an Assistant Professor of Medicine at the University of California San Diego where he practices clinically in the medical intensive care unit and in the outpatient Sleep Medicine clinic. His research is focused on obstructive sleep apnea pathogenesis, specifically understanding why different people develop sleep apnea which may allow for a personalized medicine approach to the treatment of OSA.
Dr. David Poch is an Associate Clinical Professor in the division of Pulmonary and Critical Care at UCSD. He received his MD from Brown University and completed his pulmonary and critical care fellowship training at New York University (NYU). Following his pulmonary and critical care fellowship he completed a fellowship in pulmonary vascular diseases at Stanford University.

Dr. Poch’s research and clinical interests are in pulmonary vascular disease including PAH and CTEPH. He is spearheading the development balloon pulmonary angioplasty (BPA) at UCSD and is the principal investigator for numerous clinical trials in pulmonary arterial hypertension. Particular areas of interest include balloon pulmonary angioplasty, novel therapeutic approaches to PAH and CTEPH.
Dr Victor Pretorius completed medical school at the University of Pretoria South Africa. He became a Fellow of the Royal College of Physicians and Surgeons of Canada following a cardiac surgery residency at the University of Alberta, Canada.

Following a dedicated year of training in Pulmonary thromboendarterectomy and right heart failure at UCSD he became faculty and is currently associate clinical professor of surgery and surgical director of the heart transplant and mechanical circulatory support programs.
Dr. Silva Enciso is an assistant clinical professor of medicine in the Division of Cardiology at UC San Diego School of Medicine. He is board-certified in internal medicine, cardiovascular disease, and advanced heart failure and transplant cardiology. He previously served as a staff research associate in the Division of Cardiology.

Prior to joining UC San Diego Health System, Dr. Silva Enciso was a clinical instructor of medicine at Columbia University College of Physicians and Surgeons. His clinical interests include caring for patients with advanced heart failure, ventricular assist devices and heart transplantation. His cardiovascular research interests include statin therapy and heart failure prevention, and impact stress echocardiography on outcomes in patients with dilated cardiomyopathies.

During his medical training, Dr. Silva Enciso completed a fellowship in heart failure and transplant cardiology at Columbia University Medical Center. Prior to that, he completed a cardiovascular disease fellowship, as well as his residency and internship in internal medicine at St. Luke’s-Roosevelt Hospital Center in New York City. Dr. Silva Enciso earned his medical degree from Universidad Autónoma de Baja California in Mexico, where he graduated with the highest honors.

Dr. Silva Enciso is a member of the American College of Physicians and speaks Spanish.
Pam R. Taub, MD, FACC
Associate Professor of Medicine
Director of Hannah and Gene Step Cardiac Wellness & Rehabilitation Center
Division of Cardiovascular Medicine
UC San Diego Health Systems
San Diego, CA

Pam R. Taub, MD, FACC, is a board-certified cardiologist who focuses on general and preventive cardiology. As a general cardiologist, she works with patients to diagnose and prevent heart disease, as well as manage conditions such as hypertension (high blood pressure), coronary artery disease, or heart failure.

Dr. Taub believes that prevention is the new frontier in cardiovascular medicine. She takes an evidence-based approach to care and tailors it to each patient, with the goal of minimizing medications and procedures. She also collaborates with other specialists to provide cardiac care for patients with complex, multi-system diseases such as cancer and autoimmune disease.

Dr. Taub believes in empowering and educating patients by sharing the latest advances in research and technology, and she enjoys speaking to the community about cardiovascular disease prevention.

Her own research—focused on how epicatechin (a compound found in dark chocolate) can improve mitochondrial structure and exercise capacity in patients with heart failure and diabetes—has received funding from the National Institutes of Health and the American College of Cardiology, and has resulted in multiple publications in top journals. She is also developing and testing new biomarkers (blood tests) to predict cardiovascular risk, as well as studying the mechanisms of statin-related muscle complaints and decreases in exercise capacity and using epicatechin to treat them.

Dr. Taub completed a fellowship in cardiology at UC San Diego School of Medicine, where she was chief cardiology. She completed a residency in internal at the University of Washington Medical Center and earned her medical degree at Boston University School of Medicine. She is board-certified in internal medicine, cardiovascular disease, and nuclear cardiology. Dr. Taub is a fellow of the American College of Cardiology (FACC).
Howie Tran, MD, FACC  
Assistant Professor of Medicine  
Division of Cardiovascular Medicine  
Advanced Heart Failure, Mechanical Circulatory Support and Transplant Cardiology  
UC San Diego Health Systems  
San Diego, CA

Howie Tran, MD, is an assistant clinical professor of medicine and a member of the Sulpizio Cardiovascular Center team. He is a board certified cardiologist and specializes in the care of patients with advanced heart failure, mechanical circulatory support and Dr. Tran earned his medical degree from Drexel University College of Medicine in Philadelphia. He is a graduate of the internal medicine residency program at Brown University and stayed for the completion of his cardiovascular disease fellowship. Dr. Tran then returned to California for subspecialty training in advanced heart failure, mechanical circulatory support and transplant cardiology at the University of California, San Diego.

Clinical Expertise  
- Treatment of end stage heart failure  
- Management of percutaneous mechanical circulatory support  
- Medical management of orthotopic heart transplantation  
- Management of durable ventricular assist device (VADs)